Brivaracetam API Powder CAS 357336-20-0

UCB-34714 is a highly selective and affinity synaptic vesicle protein 2A ligand. The Brivaracetam API powder used clinically is mainly used to treat partial seizures of adult epilepsy symptoms, with or without secondary systemic seizures as adjuvant therapy. Compared with the previous generation drug levetiracetam, Brivaracetam has a similar chemical structure and mechanism of action, but with lower adverse reactions. It is the first FDA approved antiepileptic product for the treatment of partial epileptic seizures since 2013.

What is the action mechanism of Brivaracetam API powder?

Brivaracetam API powder has a high affinity and can selectively bind to synaptic vesicle protein 2A (SV2A),This is a key target in epilepsy treatment.SV2A is located in the presynaptic membrane and participates in regulating the release of neurotransmitters and vesicle circulation, maintaining the normal function of synaptic vesicles.
The combination of AED Brivaracetam and SV2A can reduce the release of excitatory neurotransmitters and achieve the effect of controlling epileptic seizures by regulating the balance of excitatory and inhibitory neurotransmitters in the brain.
In a meta-analysis involving 6 randomized, placebo-controlled, single or double-blind trials, 1715 patients out of 2399 participants received Hot sales UCB 34714 treatment. The proportion of UCB-34714 API powder treatment patients who showed a 50% response (patients with seizures reduced by at least 50% from baseline) was approximately twice that of placebo ([relative risk] RR, 1.79), while the proportion of patients without seizures was nearly five times that of placebo (RR, 4.74).

What are the relative advantages of Brivaracetam API powder?

We know that epilepsy is a chronic nervous system disease caused by abnormal brain discharge. According to the latest research, controlling synaptic vesicles protein 2A(SV2A) may be more effective than traditional products that act on ion channels or excitatory-inhibitory neurotransmitters, and it is less destructive to the central nervous system, which is also the research direction of epilepsy treatment in the future. As the second generation of SV2A ligand, the mechanism of action of Brivaracetam API powder is similar to that of the first generation of LEV powder, and it further inherits the advantages that levetiracetam does not affect the synaptic transmission mediated by peptidergic butyric acid and glutamate neurons at the therapeutic concentration.
In addition, UCB-34714, as the second generation antiepileptic drug with SV2A ligand, has many obvious advantages compared with the first generation levetiracetam:
1. Brivaracetam has high affinity and can selectively bind synaptic vesicles protein 2A(SV2A), which is the key mechanism of its antiepileptic effect. By combining with SV2A, UCB-34714 can reduce the release of excitatory neurotransmitters and regulate the balance between excitatory neurotransmitters and inhibitory neurotransmitters in the brain, thus achieving the effect of controlling epileptic seizures. This mechanism is more accurate and efficient than the first generation drugs.
2. The affinity of Brivaracetam  is much higher than that of the first generation antiepileptic drugs, so its dosage is relatively low, which helps to reduce the side effects of the drugs and improve the patient's tolerance. In addition, the curative effect of UCB-34714 is also more significant, which shows a high response rate in clinical trials and can significantly reduce the frequency and severity of epileptic seizures.
3. It also has good safety. A large number of clinical trials show that most patients who use UCB-34714 have no serious adverse reactions during treatment, which makes it a safe and reliable antiepileptic drug.
4. It has a wider scope of application. It is not only suitable for patients with partial seizures, but also for the treatment of comprehensive seizures. For those patients who are ineffective or intolerant to traditional antiepileptic drugs, UCB-34714 provides a new and more effective treatment option.

What should we pay attention to in clinical use?

Brivaracetam API powder is a derivative of Cetane, which has extensive antiepileptic activity and high safety. As a novel high affinity ligand of SV2A, it can exert antiepileptic effect by binding with synaptic vesicles protein 2A(SV2A). At the same time, some studies have shown that it can also inhibit the voltage-dependent Na ion channels in the brain, inhibit the release of excitatory neurotransmitters by interacting with sodium ion channels, reduce the duration and frequency of epileptic discharges, and thus reduce the onset of epilepsy. According to a large number of clinical data, the affinity of 357336-20-0 UCB 34714 is 15-30 times that of 102767-28-2 LEV , which reduces its dosage by about 10 times.
However, the use and research of this product should be strictly in accordance with FDA requirements, and its most common adverse reaction is to reduce the activity of cerebral cortex, which leads to dizziness, fatigue, nausea/vomiting and so on.

A variety of shipping methods for you to choose

Our strengths:

Our company has passed FDA and ISO19001 quality management system certification. And we have internal cooperation agreements with multiple factories and laboratories in China,Our company can provide Brivaracetam API Powder etc. at a more favorable price. If you are interested, please leave a message.
We not only have unique advantages in transportation, but also support multiple payment methods, whether you use US dollars, euros, Australian dollars, or local currencies from Singapore, Malaysia, Thailand, and so on. We can also support local currencies in these regions and countries. In addition, we also support bank cards (credit cards, etc.) for payments.

Disclaimer: The information published on this website comes from the internet, which does not mean that this website agrees with its views or confirms the authenticity of the content. Please pay attention to distinguish it. In addition, the products provided by our company are only used for scientific research. We are not responsible for the consequences of any improper use.

If you are interested in our products, or have critical suggestions on our articles or are not completely satisfied with the products received, please contact us by Email ：sales6@faithfulbio.com   . Our team is committed to ensuring the complete satisfaction of customers.

Hot Tags: brivaracetam api powder cas 357336-20-0, China, suppliers, manufacturers, factory, customized, wholesale, buy, price, bulk, pure, producer, discount, for sale, in stock, free sample, raw powder, raw material, made in China